Galapagos NV Announces GSK2586184 JAK1 Molecule Moves Into Phase 2 For Ulcerative Colitis
MECHELEN, Belgium, Nov. 27, 2013 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) announced today that GlaxoSmithKline plan to initiate an exploratory Phase 2 study with GSK2586184 (formerly GLPG0778) in patients with ulcerative colitis, a third indication for this investigational molecule, in addition to psoriasis and lupus.
Help employers find you! Check out all the jobs and post your resume.